Insulet Corp (PODD) stock
PODDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 21/3046% below fair value
$149.29−0.74 (-0.49%)
Close on Nov 12, 2026Market cap $10.35BP/E 24.3Yield –
Insulet r&d expenses
Research and development expenses are spending on new products and technology.
Insulet's R&D Expenses for the twelve months ending Sep 30, 2026 was $360.30M, up 33.1% year over year. For fiscal 2025 it was $301.10M, up 37.1% from the year before. Over ten years it grew 21.4% a year on average. The highest annual figure on record is $301.10M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $301.10M | +37.1% |
| FY2024 | Dec 31, 2024 | $219.60M | +7.1% |
| FY2023 | Dec 31, 2023 | $205.00M | +13.8% |
| FY2022 | Dec 31, 2022 | $180.20M | +12.6% |
| FY2021 | Dec 31, 2021 | $160.10M | +9.1% |
| FY2020 | Dec 31, 2020 | $146.80M | +11.0% |
| FY2019 | Dec 31, 2019 | $132.30M | +39.6% |
| FY2018 | Dec 31, 2018 | $94.80M | +25.2% |
| FY2017 | Dec 31, 2017 | $75.70M | +35.9% |
| FY2016 | Dec 31, 2016 | $55.71M | +28.9% |
| FY2015 | Dec 31, 2015 | $43.21M | +54.9% |
| FY2014 | Dec 31, 2014 | $27.90M | +28.2% |
| FY2013 | Dec 31, 2013 | $21.77M | -10.6% |
| FY2012 | Dec 31, 2012 | $24.36M | +11.4% |
| FY2011 | Dec 31, 2011 | $21.86M | +32.0% |
| FY2010 | Dec 31, 2010 | $16.57M | +25.2% |
| FY2009 | Dec 31, 2009 | $13.23M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $91.60M | +18.7% |
| Q2 FY2026 | Jun 30, 2026 | $88.10M | +20.0% |
| Q1 FY2026 | Mar 31, 2026 | $89.70M | +50.5% |
| Q4 FY2025 | Dec 31, 2025 | $90.90M | +50.0% |
| Q3 FY2025 | Sep 30, 2025 | $77.20M | +40.6% |
| Q2 FY2025 | Jun 30, 2025 | $73.40M | +36.2% |
| Q1 FY2025 | Mar 31, 2025 | $59.60M | +18.7% |
| Q4 FY2024 | Dec 31, 2024 | $60.60M | +44.3% |
| Q3 FY2024 | Sep 30, 2024 | $54.90M | -5.0% |
| Q2 FY2024 | Jun 30, 2024 | $53.90M | -2.2% |
| Q1 FY2024 | Mar 31, 2024 | $50.20M | +0.2% |
| Q4 FY2023 | Dec 31, 2023 | $42.00M | -15.2% |
| Q3 FY2023 | Sep 30, 2023 | $57.80M | +28.4% |
| Q2 FY2023 | Jun 30, 2023 | $55.10M | +29.3% |
| Q1 FY2023 | Mar 31, 2023 | $50.10M | +16.2% |
| Q4 FY2022 | Dec 31, 2022 | $49.50M | +18.4% |
| Q3 FY2022 | Sep 30, 2022 | $45.00M | +20.0% |
| Q2 FY2022 | Jun 30, 2022 | $42.60M | +6.2% |
| Q1 FY2022 | Mar 31, 2022 | $43.10M | +5.9% |
| Q4 FY2021 | Dec 31, 2021 | $41.80M | +9.1% |
| Q3 FY2021 | Sep 30, 2021 | $37.50M | -3.4% |
| Q2 FY2021 | Jun 30, 2021 | $40.10M | +17.3% |
| Q1 FY2021 | Mar 31, 2021 | $40.70M | +14.6% |
| Q4 FY2020 | Dec 31, 2020 | $38.30M | +7.9% |
| Q3 FY2020 | Sep 30, 2020 | $38.80M | +24.0% |
| Q2 FY2020 | Jun 30, 2020 | $34.20M | +3.6% |
| Q1 FY2020 | Mar 31, 2020 | $35.50M | +9.2% |
| Q4 FY2019 | Dec 31, 2019 | $35.50M | +6.3% |
| Q3 FY2019 | Sep 30, 2019 | $31.30M | +40.1% |
| Q2 FY2019 | Jun 30, 2019 | $33.00M | +75.5% |
| Q1 FY2019 | Mar 31, 2019 | $32.50M | +60.4% |
| Q4 FY2018 | Dec 31, 2018 | $33.40M | +66.7% |
| Q3 FY2018 | Sep 30, 2018 | $22.34M | +10.9% |
| Q2 FY2018 | Jun 30, 2018 | $18.80M | +4.3% |
| Q1 FY2018 | Mar 31, 2018 | $20.27M | +15.8% |
| Q4 FY2017 | Dec 31, 2017 | $20.03M | +24.9% |
| Q3 FY2017 | Sep 30, 2017 | $20.14M | – |
| Q2 FY2017 | Jun 30, 2017 | $18.03M | – |
| Q1 FY2017 | Mar 31, 2017 | $17.50M | – |
| Q4 FY2016 | Dec 31, 2016 | $16.03M | – |
See a number that looks wrong?